EYPT
EyePoint Pharmaceuticals Inc

8,703
Mkt Cap
$1.45B
Volume
1.64M
52W High
$19.11
52W Low
$3.91
PE Ratio
-5.87
EYPT Fundamentals
Price
$18.34
Prev Close
$17.56
Open
$17.18
50D MA
$15.84
Beta
1.25
Avg. Volume
951,267.80
EPS (Annual)
-$2.32
P/B
6.10
Rev/Employee
$262,260.61
$71.61
Loading...
Loading...
News
all
press releases
Eyepoint Pharmaceuticals, Inc. $EYPT Shares Sold by Essex Woodlands Management Inc.
Essex Woodlands Management Inc. trimmed its position in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 7.3% in the third quarter, according to its most recent 13F filing with the...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Novavax (NVAX) Beats Q4 Earnings and Revenue Estimates
Novavax (NVAX) delivered earnings and revenue surprises of +116.60% and +87.65%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
Eyepoint Pharmaceuticals (EYPT) to Release Earnings on Wednesday
Eyepoint Pharmaceuticals (NASDAQ:EYPT) will be releasing its Q4 2025 earnings before the market opens on Wednesday, March 4. (View Earnings Report at...
MarketBeat·6d ago
News Placeholder
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 6% - Here's What Happened
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 6% - Still a Buy...
MarketBeat·7d ago
News Placeholder
Patient Square Capital LP Sells 340,998 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT
Patient Square Capital LP trimmed its stake in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 25.2% during the third quarter, according to its most recent filing with the...
MarketBeat·7d ago
News Placeholder
Aberdeen Group plc Sells 234,399 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT
Aberdeen Group plc lowered its position in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 22.7% in the 3rd quarter, according to its most recent Form 13F filing with the...
MarketBeat·11d ago
News Placeholder
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 4.4% - Time to Sell?
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 4.4% - What's Next...
MarketBeat·12d ago
News Placeholder
EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains?
EyePoint (EYPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·12d ago
News Placeholder
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Sees Unusually-High Trading Volume - Time to Buy?
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Sees Large Volume Increase - What's Next...
MarketBeat·13d ago
News Placeholder
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of "Buy" by Brokerages
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has been given a consensus rating of "Buy" by the seven brokerages that are covering the company, Marketbeat.com reports. One research...
MarketBeat·15d ago
<
1
2
...
>

Latest EYPT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.